Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 24Recruiting 8Unknown 6Terminated 5Active not recruiting 3Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Gastrointestinal 145Head & Neck 18Breast 12Tumor-Agnostic 5Gynecologic 4Dermatologic 4Thoracic 3Other solid neoplasm 3Genitourinary 3Sarcoma 2Other hematologic neoplasm 2Lymphoid 2Endocrine 2Plasma cell 1Other 1NET 1Myeloid 1Classical hematology 1

Conditions

Neoplasms 4Carcinoma, Squamous Cell 1

Interventions

Gemcitabine 13pembrolizumab 12Capecitabine 9Irinotecan 8Erlotinib Hydrochloride 8Carboplatin 8Blood Specimen Collection 8Nivolumab 7Docetaxel 7Cisplatin 7Cetuximab 7Paclitaxel 6Everolimus 6130-nm albumin-bound paclitaxel 6vadimezan 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cyclophosphamide 5trametinib 4Leucovorin 4Lapatinib 4Ipilimumab 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3atezolizumab 3abemaciclib 3Trastuzumab 3Radiotherapy 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × Fluorouracil × Tumor-Agnostic × Clear all
NCT02420509 2025-06-04

Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis

University of California, San Diego

Terminated
2 enrolled
Tumor-Agnostic

Neoplasms

NCT03387111 2024-08-05

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed

ImmunityBio, Inc.

Phase 1/2 Terminated
4 enrolled 14 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

NCT00954512 2018-08-24

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
15 enrolled 11 charts
Tumor-Agnostic

Neoplasms

NCT02241551 2018-07-26

Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

University of Pittsburgh

Phase 2 Terminated
2 enrolled 7 charts
Tumor-Agnostic

Neoplasms

NCT01271166 2011-01-06

GlivecĀ® Plus m-FOLFOX AvastinĀ® in Advanced Colorectal Cancer

Novartis

Phase 1 Terminated
10 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔